Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1977 1
1978 2
1979 1
1982 1
1984 1
1986 2
1987 3
1988 1
1990 1
1991 1
1992 2
1994 1
1995 4
1996 1
1997 4
1998 5
1999 4
2000 4
2001 4
2002 5
2003 2
2004 4
2005 5
2006 3
2007 2
2008 6
2009 11
2010 14
2011 2
2012 17
2013 23
2014 31
2015 25
2016 18
2017 33
2018 40
2019 34
2020 50
2021 51
2022 29
2023 39
2024 38
2025 44
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Results by year

Filters applied: Clinical Trial, Humans. Clear all
Page 1
Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker.
Hu H, Lee Y, Tillman AN, Ballard ED, Waldman L, Yuan P, Johnston JN, Peng S, Kvarta MD, Verbalis JG, Zarate CA Jr. Hu H, et al. J Neuroendocrinol. 2026 Jan;38(1):e70133. doi: 10.1111/jne.70133. J Neuroendocrinol. 2026. PMID: 41555748 Clinical Trial.
This study used copeptin, a stable, reliable, and well-validated surrogate marker of AVP secretion, to assess vasopressinergic function in a transdiagnostic sample of individuals experiencing a major depressive episode (MDE) with and without post-traumatic stress disord …
This study used copeptin, a stable, reliable, and well-validated surrogate marker of AVP secretion, to assess vasopressinergic function in a …
Single fixed-dose intranasal racemic ketamine treatment for the treatment of acute suicidality in a transdiagnostic patient population: Results of a pilot study.
Roelandt GHJ, Strous JFM, Marijnissen RM, Kamphuis J, van Dalfsen JH, Schoevers RA. Roelandt GHJ, et al. Psychiatry Res. 2026 Mar;357:116909. doi: 10.1016/j.psychres.2025.116909. Epub 2025 Dec 16. Psychiatry Res. 2026. PMID: 41456567 Free article. Clinical Trial.
AIMS: Ketamine has been shown to decrease suicidality in patients with depression. However, little is known about tolerability and efficacy in heterogenous, acutely suicidal patients in emergency settings. ...All received a single open-label dose of 75 mg intranasal …
AIMS: Ketamine has been shown to decrease suicidality in patients with depression. However, little is known about tolerability …
Acute traumatic pain treatment with ketamine decreased PTSD and anxiety symptoms 6 months post hospital discharge.
Trevino CM, Carver T, Tomas C, Larson C, Mantz-Wichman M, Peppard WJ, deRoon-Cassini T. Trevino CM, et al. J Trauma Acute Care Surg. 2026 Feb 1;100(2):215-220. doi: 10.1097/TA.0000000000004835. Epub 2025 Dec 17. J Trauma Acute Care Surg. 2026. PMID: 41417647 Clinical Trial.
BACKGROUND: Chronic pain, anxiety, depression, and posttraumatic stress disorder (PTSD) are frequently seen after traumatic injury. ...We hypothesized patients receiving ketamine would have a lower incidence of chronic pain, anxiety, depression, and PT …
BACKGROUND: Chronic pain, anxiety, depression, and posttraumatic stress disorder (PTSD) are frequently seen after traumatic in …
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.
Durgam S, Earley WR, Kozauer SG, Mo Y, Lakkis H, Edwards JB, Kornstein SG, Fava M. Durgam S, et al. Am J Psychiatry. 2025 Dec 1;182(12):1072-1082. doi: 10.1176/appi.ajp.20250292. Epub 2025 Dec 1. Am J Psychiatry. 2025. PMID: 41320817 Clinical Trial.
OBJECTIVE: This phase 3, randomized, double-blind, placebo-controlled trial evaluated lumateperone 42 mg (a simultaneous modulator of serotonin, dopamine, and glutamate neurotransmission) adjunctive to antidepressant therapy (ADT) in patients with major depressive disor …
OBJECTIVE: This phase 3, randomized, double-blind, placebo-controlled trial evaluated lumateperone 42 mg (a simultaneous modulator of seroto …
Model-based planning is unaffected by ketamine, antidepressant and internet delivered cognitive behavioural therapy treatments in depression.
Donegan KR, Hossein S, Panny BM, Brown VM, Lee CT, Harty S, Lynch K, Fox C, Hanlon AK, O'Keane V, Stephan KE, Gillan CM, Price RB. Donegan KR, et al. Transl Psychiatry. 2025 Nov 27;15(1):505. doi: 10.1038/s41398-025-03722-8. Transl Psychiatry. 2025. PMID: 41309552 Free PMC article. Clinical Trial.
Across two parallel studies, participants completed a two-step reinforcement learning paradigm before and after antidepressant medication, internet-based cognitive behavioral therapy (iCBT) or intravenous (IV) ketamine infusion. In experiment 1, 93 patients with treatment- …
Across two parallel studies, participants completed a two-step reinforcement learning paradigm before and after antidepressant medication, i …
Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder.
Greene BD, Fijtman A, Yalin N, Kvarta MD, Wang PR, Yavi M, Greenstein D, Zarate CA Jr. Greene BD, et al. J Affect Disord. 2026 Feb 15;395(Pt B):120780. doi: 10.1016/j.jad.2025.120780. Epub 2025 Nov 25. J Affect Disord. 2026. PMID: 41308888 Clinical Trial.
BACKGROUND: No clinically useful biomarkers currently predict antidepressant response to ketamine in treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD). ...TSH levels were not associated with changes in depression, anhe …
BACKGROUND: No clinically useful biomarkers currently predict antidepressant response to ketamine in treatment-resistant major dep …
Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study.
Dawson KL, Carangan AMJM, Klunder J, Carreras-Gallo N, Sehgal R, Megilligan S, Askins BC, Perkins N, Mendez TL, Smith RM, Dawson MS, Mallin MP, Higgins-Chen AT, Dwaraka VB. Dawson KL, et al. Transl Psychiatry. 2025 Oct 31;15(1):452. doi: 10.1038/s41398-025-03683-y. Transl Psychiatry. 2025. PMID: 41173838 Free PMC article. Clinical Trial.
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. ...Ketamine's effects on biological aging have no …
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associ …
Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial.
Jelovac A, McCaffrey C, Terao M, Shanahan E, Whooley E, McDonagh K, McDonogh S, Loughran O, Shackleton E, Igoe A, Thompson S, Mohamed E, Nguyen D, O'Neill C, Walsh C, McLoughlin DM. Jelovac A, et al. JAMA Psychiatry. 2025 Dec 1;82(12):1216-1224. doi: 10.1001/jamapsychiatry.2025.3019. JAMA Psychiatry. 2025. PMID: 41123905 Free PMC article. Clinical Trial.
Participants included adults (18 years) hospitalized with a DSM-5 major depressive episode (unipolar or bipolar) and baseline Montgomery-Asberg Depression Rating Scale (MADRS) score 20. ...CONCLUSIONS AND RELEVANCE: Serial adjunctive ketamine infusions were n …
Participants included adults (18 years) hospitalized with a DSM-5 major depressive episode (unipolar or bipolar) and baseline Montgom …
Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis.
Silberbauer LR, Eggerstorfer B, Michenthaler P, Reichel S, Stimpfl T, Vanicek T, Naderi-Heiden A, Kasper S, Lanzenberger R, Gryglewski G. Silberbauer LR, et al. J Affect Disord. 2026 Feb 1;394(Pt A):120466. doi: 10.1016/j.jad.2025.120466. Epub 2025 Oct 14. J Affect Disord. 2026. PMID: 41101490 Free article. Clinical Trial.
Forty-five patients diagnosed with a moderate to severe depressive episode received either 1 mg/kg peroral ketamine or 0.03 mg/kg midazolam solution as an active comparator, administered six times over two weeks in a double-blind trial. ...Despite that the current t …
Forty-five patients diagnosed with a moderate to severe depressive episode received either 1 mg/kg peroral ketamine or 0.03 mg …
Evaluation of Low-Dose Ketamine and Dexmedetomidine Compared to Morphine for Control of Traumatic Limb Pain in the Emergency Department: A Randomized Clinical Trial.
Moradi MM, Barootchi E, Najmeddin F, Sotoodehnia M, Barikro N, Khanlarzadeh M, Jalali A. Moradi MM, et al. J Emerg Med. 2025 Nov;78:379-388. doi: 10.1016/j.jemermed.2025.03.025. Epub 2025 Mar 27. J Emerg Med. 2025. PMID: 41033020 Clinical Trial.
BACKGROUND: Opioids have been traditionally used for acute pain management; however, they are associated with side effects, including respiratory depression, physical dependence, and potential misuse. Ketamine is known to be an effective agent in reducing pain with …
BACKGROUND: Opioids have been traditionally used for acute pain management; however, they are associated with side effects, including respir …
484 results